《Table 6 Adverse events and infections in the study cohort listed according to the time of their occ

《Table 6 Adverse events and infections in the study cohort listed according to the time of their occ   提示：宽带有限、当前游客访问压缩模式
本系列图表出处文件名：随高清版一同展现
《Ustekinumab: “Real-world” outcomes and potential predictors of nonresponse in treatment-refractory Crohn's disease》


  1. 获取 高清版本忘记账户？点击这里登录
  1. 下载图表忘记账户？点击这里登录

In conclusion，our data strongly suggest that ustekinumab is effective in treatmentrefractory，moderate to severe CD under“real-world”conditions.In particular，more data is needed on the long-term safety of this drug and on potential predictors of response.

图表编号XD0087253200    严禁用于非法目的
绘制时间2019.08.21
作者Peter Hoffmann、Johannes Krisam、Cyrill Wehling、Petra Kloeters-Plachky、Yvonne Leopold、Nina Belling、Annika Gauss
绘制单位Department of Gastroenterology and Hepatology, University Hospital Heidelberg、Department of Medical Biometry, University Hospital Heidelberg、Department of Gastroenterology and Hepatology, University Hospital Heidelberg、Department of Gastroenterology and H
更多格式高清、无水印（增值服务）

相关图表

  1. 《Table 3Adverse events,serious adverse events,and concurrent treatment.》2020.10.01
  2. 《Table 1 List of plant species used in this study and their growth form in parentheses.》2019.10.01
  3. 《Table 3 Studies included in for study of plasmapheresis in acute liver failure in pediatric cohort》2020.01.14
  4. 《Table 3 Studies included in for study of plasmapheresis in acute liver failure in pediatric cohort》2020.01.14
  5. 《Table 2 Quality assessment of included observational cohort and cross-sectional studies according to NHBLI Quality Asses》2019.07.27
  6. 《Table 2 Quality assessment of included observational cohort and cross-sectional studies according to NHBLI Quality Asses》2019.07.27
  7. 《Table 2 Stratified analysis of overall survival in GSE14520 and The Cancer Genome Atlas cohorts》2019.04.14
  8. 《Table 3 Univariate and multivariate analyses of prognostic parameters for survival in the cohort patients with gastric n》2019.04.14
  9. 《Table 1 Scales and studies in the meta-analysis》2019.01.10
  10. 《Table 1 Scales and studies in the meta-analysis》2019.01.10
  11. 《Table 5.IVIG dose and the total types of adverse reactions and intervention during the events.》2019.01.01
  12. 《Table 2 Comparison of acute adverse events between NDP and DDP group》2019.02.20
  13. 《表6 研究期间患者不良事件发生情况Tab.6 The occurrence of adverse events with patients during the study》2019.02.15
  14. 《Table 1.Characteristics of the Study Cohort at Baseline in 2002 (n=204)》2019.03.20
  15. 《Table 2 List of the Landsat data[22]used in this study》2018.12.24
  16. 《Table 1.List of the CMIP5 models and their ensemble members used in this study, where“high top”indicates a model with a》2018.01.10
  17. 《表1 本文分析所选用的厄尔尼诺/拉尼娜事件及其特征值Tab.1 The El Nio/La Nia events selected in this study and their characteristics》2018.01.25
  18. 《Table 5 Adverse events during the study treatment》2018.03.01
  19. 《表3 两组不良反应发生情况比较 (n) Table 3 Comparison of adverse events in both groups (n)》2018.01.25
  20. 《表3 研究组与对照组不良反应发生情况对比 (n) Table 3 Comparison of adverse reactions between the study group and the control group (n)》2018.01.25

随机翻阅

《表5 效度检验：唐代织锦中含绶鸟纹的设计因子提取及应用研究》 《表3 镀铬后衔铁与线圈骨架间隙》 《表4 上水线附近水膜厚度变化主频》 《表2 算法比较列表：2I2C用户流失建模分析》 《表2 不同品种轮作作物地上部甲醇浸提液刺激瓜列当种子发芽 (%)》 《表2 面板数据的描述性结果》 《Table 7 Unitary regression analysis results of the Fitts’law model under full visual feedback表7全视觉反馈下Fitts’law模b一元回归分析结果》 《表4 2014-2017年平山县金融基础服务设施覆盖范围》 《表2 2012级满意程度模糊关系子集》 《表2 两组临床疗效比较[n (%) ]》